Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
IMPROEV trial: what clinicians have said so far
Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma
- NCT07221942 ↗
- Recruiting
- Fox Chase Cancer Center
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on IMPROEV (enfortumab vedotin plus pembrolizumab) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on IMPROEV so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 4 posts on X, typically up to 18 once built | |
| 1 YouTube video, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- Pembrolizumab Maintenance After Enfortumab Vedotin/Pembrolizumab Induction in Front-Line Metastatic Urothelial Carcinoma
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Metastatic Urothelial Carcinoma; Unresectable Urothelial Carcinoma; Advanced Urothelial Carcinoma
- Interventions
- Enfortumab vedotin; Pembrolizumab
- Arms
- Induction EV + Pembrolizumab Followed by Maintenance Pembrolizumab · Experimental
- Enrollment
- 97 (estimated)
- Primary outcomes
- 18-month progression-free survival (PFS)
- Sponsor
- Fox Chase Cancer Center with United States Department of Defense
- Start
- Jan 23, 2026
- Primary completion
- Sep 1, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT07221942 · updated Feb 19, 2026